I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

SITC 2023

Coming soon
04:00 PM
Duration 10hrs San Diego, USA
Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab ± bevacizumab + carboplatin-paclitaxel in metastatic NSCLC
Tianshi Lu, Mark Socinski, Martin Reck, Howard Jack West, Federico Cappuzzo, Fabrice Barlesi, Robert M Jotte, Soeren Mueller, Habib Hamidi, Assaf Amitai, Hartmut Koeppen, David S Shames, Marcus Ballinger, Minu K Srivastava, Barzin Nabet

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 10hrs San Diego, USA
A Phase I study of a tumor-targeted fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors
Ignacio Melero, Julia Lostes Bardaji, Iben Spanggaard, Dae Ho Lee, James Spicer, Fiona Thistlethwaite, Stefan Symeonides, Do-Youn Oh, Antoine Hollebecque, Corinne Rusterholz, Olivera Cirovic, Yvonne Zhao,Nicole A Kratochwil, Bernhard Reis, Alexandra Epp, Georgios Kazantzidis, Victor Moreno

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 10hrs San Diego, USA
TIGIT and PD-L1 co-blockade promotes functional differentiation and clonal expansion of antitumor CD8+ T cells resistant to exhaustion programming
Katherine N. Nutsch, Karl Banta, Thomas D. Wu, Charles Tran, Stephanie Mittman, Ellen Duong, Barzin Nabet, Yan Qu, Namrata S. Patil, Eugene Y. Chiang, Ira Mellman

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:55 PM
Duration 120mins Presented during Session: Stromal Cells and TLS
IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy
Minu K. Srivastava, VelimirGayevskiy, VyMa, Ivette Estay, Miguel Lopez de Rodas, Barani Kumar Rajendran, Tien Hoang, Marcus Ballinger, Reena Amin, Roy S. Herbst, Filippo De Marinis, Giuseppe Giaccone, Jacek Jassem, David Spigel, Kurt Schalper, Hartmut Koeppen, David S. Shames, Robert Johnston, Jennifer Giltnane, Barzin Y. Nabet

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar